Kristof Vercruysse is a highly accomplished biopharmaceutical executive with over 20 years of experience in bringing biopharmaceutical compounds from preclinical proof of concept towards market authorization. He received his Masters in Biomedical Science from Vrije Universiteit Brussel and has since dedicated his career to advancing the field of biotechnology.
Kristof gained hands-on experience with the development of Caplacizumab for the treatment of TTP during his time at Ablynx from 2007 to 2013. After leaving Ablynx, he joined Sourcia, a full-service boutique CRO that delivers tailor-made clinical drug development for biotech companies. There he honed his expertise in the development of biopharmaceuticals and gained valuable insights into the clinical trial process.
Currently, Kristof holds the position of Chief Executive Officer at TargED Biopharmaceuticals, a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis. With his extensive experience in biopharmaceutical development, Kristof is well-equipped to lead TargED towards its goal of improving patient outcomes through the development
of innovative and effective treatments for thrombosis.